CLINICAL_TRIALS
trial_result
· 2016-01-28
Clinical Trial Update: Effect of Ruboxistaurin on Clinically Significant Macular Edema [Phase 3]
Summary
Phase 3 trial evaluating ruboxistaurin for clinically significant macular edema in diabetes has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chromaderm, Inc. | Conditions: Diabetic Macular Edema | Phase 3 | Status: COMPLETED | Results posted: 2016-01-28